Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Jefferies 2017 Global Healthcare Conference
28 slides from Indivior Pharmaceuticals's conference presentation, Jun 6, 2017
Slide 1: Strengthening our global leadership in treatment of addiction
Strengthening our global leadership in treatment of addiction Jefferies 2017 Global Healthcare Conference June 6th, 2017
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains certain statements that are forward-looking and which should be considered, amongst other statutory provisions, in light of the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995. By their nature, forwar
Slide 3: Why Indivior?
Why Indivior? 1 Targeting a global epidemic – addiction and its co-morbidities 2 Building on leading Buprenorphine Medication-Assisted Treatment (BMAT) position to develop and commercialize novel, break-through addiction treatments 3 Generating strong profitability and cash flow today with future up
Slide 4: Indivior PLC (LON: INDV) Snapshot
Indivior PLC (LON: INDV) Snapshot 2016 Operating Highlights (1) 2016 Sales by Geography (2) $1.05 bil. (+4% vs. 2015) Net revenue 19% $387 mil. (37% margin) ROW Adj. operating profit (3) $692 mil. $1.05 Cash balance bil. 40 19% Europe 81% Countries of presence U.S. 965 Employees worldwide (1) Indivi
Slide 5: Addiction
Addiction The scale of the problem
Slide 6: Our Vision
OUR VISION For all patients around the world to have access to quality treatment for the chronic relapsing condition and co-morbidities of addiction
Slide 7: Treating Addiction is our Primary Focus
Treating Addiction is our Primary Focus (2) Addiction affects millions globally • 29 mil. people aged 15 to 64 suffer from drug use disorders or drug dependence (1) • 3.6 mil. years of life were lost due to premature death caused by drug use in 2010 (2) • 55% of the lost years were due to premature
Slide 8: Opioid Use Disorder is an Epidemic in the U.S.
Opioid Use Disorder is an Epidemic in the U.S. (2) THE EQUIVALENT OF A PASSENGER PLANE CRASHING EVERY DAY = WITH NO SURVIVORS (3) (1) 4 PEOPLE IN THE US DIE OF OPIOID OVERDOSE EVERY HOUR OF EVERY DAY Stories like the shocking Ohio overdose one last September are becoming all too common (1) CDC: http
Slide 9: The U.S. Represents a Tremendous Growth Opportunity
The U.S. Represents a Tremendous Growth Opportunity • 80% of world’s opioid users Largest Market (1) • 300 million pain prescriptions written in 2015 worth $24 billion • Medication-assisted treatment (MAT) endorsed by U.S. government Conducive Policy (2) • CARA legislation and CURES Act increased ad
Slide 10: Film Share Remains Resilient
Generic bup/nal tablets launched Zubsolv tablet launched CVS formulary loss United formulary loss and 3rd generic tablet approved Source: Symphony Health Solutions Retail PHAST Weekly Prescription Data week ending March 31, 2017 Film Share Remains Resilient Bunavail launch CVS formulary change 10
Slide 11: Ex-US Markets in Earlier Stage of Development
Ex-US Markets in Earlier Stage of Development EU (>1 mil. problem opioid users) differs from US as opioid- dependence mainly heroin addiction (1) Policy focused more on harm reduction for society than on patient recovery Methadone clinics, strict supervision prevail Volume growing slowly, valu
Slide 12: The Pipeline
The Pipeline SZ INDIVIOR AS
Slide 13: Key Pipeline Assets Have Sales Potential of >$2 billion
Key Pipeline Assets Have Sales Potential of >$2 billion Stage of Development Status(1) Buprenorphine Lifecycle Phase 1 Phase II Phase III NDA Efficacy Safety Launch Peak Net Rev. Forecast (2) Fast Track Designation 5/23/16 Ph. III Ph. III RBP-6000 Submitted Achieved primary & Q1 2018 ≥$1 bil. se
Slide 14: Key Phase 3 Asset: RBP-6000 for Opioid Use Disorder
Key Phase 3 Asset: RBP-6000 for Opioid Use Disorder Unmet Patient Needs RBP-6000 Treatment What: Once monthly buprenorphine depot injection in the Atrigel® >2 5 <50% . mil. Where: U.S., initially delivery system patients diagnosed of diagnosed with OUD in the US (1) patients receive any MAT (1) When
Slide 15: Objective: Address Current Unmet Medical Needs in BMAT
Objective: Address What We Believe the Current Unmet Medical Needs are in BMAT 1 Sustained plasma levels of buprenorphine that translate into high µ-opioid receptor occupancy to suppress withdrawal symptoms and block the subjective and objective effects of opioid agonists 2 Once-monthly buprenorph
Slide 16: Key Phase 3 Asset: RBP-7000 for Schizophrenia
Key Phase 3 Asset: RBP-7000 for Schizophrenia Unmet Patient Needs RBP-7000 Treatment What: Once monthly Risperidone in 23 mil. 76% Atrigel® Where: U.S. People worldwide of patients initiated on affected by long-acting injectables When:(3) Targeting Q417 NDA; schizophrenia (1) have concurrent oral an
Slide 17: Objective: Address Unmet Needs in Long Acting Antipsychotics
Objective: Address What We Believe the Current Unmet Needs are in Long Acting Antipsychotics We believe that the following characteristics are potential differentiating attributes for future LAIs treating psychosis(1): 1 Rapid onset 2 Extended treatment duration 3 Manageable tolerability 4 No or
Slide 18: Litigation Update
LITIGATION UPDATE “2 INDIVIOR ASN
Slide 19: Major Litigation
Major Litigation The Group carries a provision of $218m for the investigative and antitrust litigation matters noted below. The Group continues in discussions with the Department of Justice about a possible resolution to its investigation. The Group cannot predict with any certainty whether we will
Slide 20: Priorities for 2017
PRIORITIES FOR 2017 “2 INDIVIOR ASN
Slide 21: Guidance for 2017
Guidance for 2017 2017 Guidance vs. 2016 Net Revenue $1,050 to $1,080 mil. $1,058 mil. Net Income (adjusted) $200 to $220 mil. $254 mil. Assumptions • No material change in current market conditions • Investment of $40 to $60 mil. in driving long- No major deterioration in generic tablet pricing t
Slide 22: Q1 2017 Highlights
Q1 2017 Highlights Financial Highlights (1) Operational Highlights (1) Reported • Support for medication-assisted Y/Y treatment (MAT) continues to grow 2017 (Δ%) (In $m, except EPS) • US market growth low double digits Net Revenue 265 3% • List pricing was up, but was offset by Operating Profit 128
Slide 23: Priorities for 2017
Priorities for 2017 Resolve legal risks and secure long-term certainty for Company 1.Suboxone Film 2. Ensure Successful 3. Expand Global 4. Prepare for possible Resilience launch for Pipeline treatment BD / M&A Preserve leadership products filing NDAs • Expand treatment • Pay down debt and position
Slide 24: Agenda for 2017
Agenda for 2017 Date Activity Event Q2 ending June 30th June 29th RBP-6000 Conference Call RBP-6000 Phase III efficacy, safety & HEOR data Q3 ending September 30th July 27th Half Year 2017 Financial Results Presentation in London (webcast live) Sept Morgan Stanley Healthcare Conference Presentation
Slide 25: Summary
Summary We are making We look forward We face the progress in managing the to continuing our future with progress to create confidence risks to the shareholder value business
Slide 26: Important Safety Information
IMPORTANT SAFETY INFORMATION Indication SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) is a prescription medicine indicated for treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Treatment should be in
Slide 27: Thank You
THANK YOU. hn INDIVIOR
Slide 28: Strengthening our global leadership in treatment of addiction
Strengthening our global leadership in treatment of addiction
Indivior — Jefferies 2017 Global Healthcare Conference on 6ix